Effect Of Rilapladib (SB-659032) On Platelet Aggregation

14:12 EDT 28th May 2015 | BioPortfolio

Summary

The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic

Conditions

Healthy Subjects

Intervention

Rilapladib (SB-659032)

Location

GSK Investigational Site
Randwick
New South Wales
Australia
2031

Status

Completed

Source

GlaxoSmithKline

Results (where available)

View Results

Links

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks

A study in patients with atherosclerosis to assess safety, effect and PK of rilapladib vs. placebo over 12 weeks of dosing.

Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers

Rilapladib is a potent and selective inhibitor of lipoprotein associated phospholipase A2 (Lp-PLA2), which was previously under development for the treatment of atherosclerosis and is curr...

PubMed Articles [4219 Associated PubMed Articles listed on BioPortfolio]

An association between temporomandibular disorder and gum chewing.

This single center, randomized, small study sought to investigate the prevalence and frequency of chewing gum consumption, and whether there is a relationship between these factors and the presence of...

Acute Porphyrias in the USA: Features of 108 Subjects from Porphyria Consortium.

Recent descriptions of the clinical and laboratory features of subjects with acute porphyrias in the US are lacking. Our aim was to describe clinical, biochemical and genetic features of 108 subjects.

Thyroid function is associated with non-alcoholic fatty liver disease in euthyroid subjects.

Abstract Objectives: This study was designed to test the hypothesis that normal thyroid function is associated with non-alcoholic fatty liver disease (NAFLD) in euthyroid general subjects. Methods: A ...

Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects.

Objective: To evaluate the effect of ethnicity on the pharmacokinetics (PK) of tildrakizumab, a novel anti-IL-23 monoclonal antibody for the treatment of psoriasis. Materials and methods: This was an ...

Association of the Renal Resistive Index with Microvascular Complications in type 2 Diabetic Subjects.

Chronic complications are the leading causes of morbidity and mortality in the diabetic population. The intrarenal resistive index (RI) has been reported to be increased in hypertensive subjects with ...

Medical and Biotech [MESH] Definitions

Books intended for use in the study of specific subjects, containing systematic presentation of the principles and essential knowledge of the subjects.

A type of analysis in which subjects in a study group and a comparison group are made comparable with respect to extraneous factors by individually pairing study subjects with the comparison group subjects (e.g., age-matched controls).

Studies in which a number of subjects are selected from all subjects in a defined population. Conclusions based on sample results may be attributed only to the population sampled.

Persons who are enrolled in research studies or who are otherwise the subjects of research.

Hospital or other institutional committees established to protect the welfare of research subjects. Federal regulations (the "Common Rule" (45 CFR 46)) mandate the use of these committees to monitor federally-funded biomedical and behavioral research involving human subjects.

More From BioPortfolio on "Effect Of Rilapladib (SB-659032) On Platelet Aggregation"

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

The Top 100 Pharmaceutical Companies
Latest News Clinical Trials Research Drugs Reports Corporate
Top 100 Pharmaceutical Companies 2012 (SCRIP 100 - http://www.scrip100.com/scrip100.html) Rank (2011 in Brackets) Company SEARCH FOR COMPANY IN BIOPORTFOLIO'S BIOCORPORATE DATABASE 2012 pharma sales...

Advertisement

Searches Linking to this Trial